Atorvastatin-induced cardioprotection of human myocardium is mediated by the inhibition of mitochondrial permeability transition pore opening via tumor necrosis factor-α and janus kinase/signal transducers and activators of transcription pathway

Anesthesiology

Volumn 118, Issue 6, 2013, Pages 1373-1384

  Lemoine, Sandrine ^a   Zhu, Lan ^b   Legallois, Damien ^b   Massetti, Massimo ^b   Manrique, Alain ^a   Hanouz, Jean Luc ^b  

^a France   (France)

^b CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; ATRACTYLOSIDE; CYCLOSPORIN A; JANUS KINASE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; STAT3 PROTEIN; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA;

ARTERY CONSTRICTION; ARTICLE; CONTROLLED STUDY; HEART MUSCLE; HEART PROTECTION; HUMAN; HUMAN TISSUE; HYPOXIA; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REOXYGENATION; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; CARDIOTONIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPTANOIC ACIDS; HUMANS; JANUS KINASES; MALE; MIDDLE AGED; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PYRROLES; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878662509     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e31828a7039     Document Type: Article

References (31)

1. Hindler K, Shaw AD, Samuels J, Fulton S, Collard CD, Riedel B: Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology 2006; 105:1260-72; quiz 1289-90
2. L e Manach Y, Ibanez Esteves C, Bertrand M, Goarin JP, Fléron MH, Coriat P, Koskas F, Riou B, Landais P: Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing vascular surgery. Anesthesiology 2011; 114:98-104
3. S chouten O, Boersma E, Hoeks SE, Benner R, van Urk H, van Sambeek MR, Verhagen HJ, Khan NA, Dunkelgrun M, Bax JJ, Poldermans D; Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group: Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med 2009; 361:980-9
4. Birnbaum Y, Lin Y, Ye Y, Martinez JD, Huang MH, Lui CY, Perez-Polo JR, Uretsky BF: Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin. Am J Physiol Heart Circ Physiol 2007; 292:H2891-7
5. Birnbaum Y, Ye Y, Rosanio S, Tavackoli S, Hu ZY, Schwarz ER, Uretsky BF: Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res 2005; 65:345-55
6. Atar S, Ye Y, Lin Y, Freeberg SY, Nishi SP, Rosanio S, Huang MH, Uretsky BF, Perez-Polo JR, Birnbaum Y: Atorvastatininduced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol 2006; 290:H1960-8
7. Y e Y, Martinez JD, Perez-Polo RJ, Lin Y, Uretsky BF, Birnbaum Y: The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Am J Physiol Heart Circ Physiol 2008; 295:H343-51
8. Bell RM, Yellon DM: Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 2003; 41:508-15
9. H ausenloy DJ, Yellon DM: Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 2006; 70:240-53
10. L acerda L, Somers S, Opie LH, Lecour S: Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc Res 2009; 84:201-8
11. Y ou L, Li L, Xu Q, Ren J, Zhang F: Postconditioning reduces infarct size and cardiac myocyte apoptosis via the opioid receptor and JAK-ST AT signaling pathway. Mol Biol Rep 2011; 38:437-43
12. Morin D, Assaly R, Paradis S, Berdeaux A: Inhibition of mitochondrial membrane permeability as a putative pharmacological target for cardioprotection. Curr Med Chem 2009; 16:4382-98
13. L emoine S, Allouche S, Coulbault L, Cornet V, Massetti M, Galera P, Gérard JL, Hanouz JL: Mechanisms involved in cardioprotective effects of pravastatin administered during reoxygenation in human myocardium in vitro. Anesthesiology 2012; 116:824-33
14. Dobrev D, Ravens U: Remodeling of cardiomyocyte ion channels in human atrial fibrillation. Basic Res Cardiol 2003; 98:137-48
15. Amour J, Kersten JR: Diabetic cardiomyopathy and anesthesia: Bench to bedside. Anesthesiology 2008; 108:524-30
16. Paradise NF, Schmitter JL, Surmitis JM: Criteria for adequate oxygenation of isometric kitten papillary muscle. Am J Physiol 1981; 241:H348-53
17. G uo CX, Pei Q, Yin JY, Peng XD, Zhou BT, Zhao YC, Wu LX, Meng XG, Wang G, Li Q, Ouyang DS, Liu ZQ, Zhang W, Zhou HH : Effects of Ginkgo biloba extracts on pharmacokinetics and efficacy of atorvastatin based on plasma indices. Xenobiotica 2012; 42:784-90
18. S hanmuganathan S, Hausenloy DJ, Duchen MR, Yellon DM: Mitochondrial permeability transition pore as a target for cardioprotection in the human heart. Am J Physiol Heart Circ Physiol 2005; 289:H237-42
19. Chopra V, Wesorick DH, Sussman JB, Greene T, Rogers M, Froehlich JB, Eagle KA, Saint S: Effect of perioperative statins on death, myocardial infarction, atrial fibrillation, and length of stay: A systematic review and meta-analysis. Arch Surg 2012; 147:181-9
20. Reddy GD, Reddy AG, Rao GS, Kumar MV: Pharmacokinetic interaction of garlic and atorvastatin in dyslipidemic rats. Indian J Pharmacol 2012; 44:246-52
21. Wolfrum S, Dendorfer A, Schutt M, Weidtmann B, Heep A, Tempel K, Klein HH, Dominiak P, Richardt G: Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol 2004; 44:348-55
22. Bolli R, Dawn B, Xuan YT : Role of the JAK-ST AT pathway in protection against myocardial ischemia/reperfusion injury. Trends Cardiovasc Med 2003; 13:72-9
23. G ross ER, Hsu AK, Gross GJ: The JAK/ST AT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of ST AT3, Akt, and GS K-3 beta. Am J Physiol Heart Circ Physiol 2006; 291:H827-34
24. H ilfiker-Kleiner D, Hilfiker A, Fuchs M, Kaminski K, Schaefer A, Schieffer B, Hillmer A, Schmiedl A, Ding Z, Podewski E, Podewski E, Poli V, Schneider MD, Schulz R, Park JK, Wollert KC, Drexler H: Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res 2004; 95:187-95
25. S mith CC, Dixon RA, Wynne AM, Theodorou L, Ong SG, Subrayan S, Davidson SM, Hausenloy DJ, Yellon DM: Leptininduced cardioprotection involves JAK/ST AT signaling that may be linked to the mitochondrial permeability transition pore. Am J Physiol Heart Circ Physiol 2010; 299:H1265-70
26. G ao Q, Zhang SZ, Cao CM, Bruce IC, Xia Q: The mitochondrial permeability transition pore and the Ca2+-activated K+ channel contribute to the cardioprotection conferred by tumor necrosis factor-alpha. Cytokine 2005; 32:199-205
27. L im HW, Lim HY, Wong KP: Uncoupling of oxidative phosphorylation by curcumin: Implication of its cellular mechanism of action. Biochem Biophys Res Commun 2009; 389:187-92
28. Y u CK, Li YH, Wong GT, Wong TM, Irwin MG: Remifentanil preconditioning confers delayed cardioprotection in the rat. Br J Anaesth 2007; 99:632-8
29. Mariani J, Ou R, Bailey M, Rowland M, Nagley P, Rosenfeldt F, Pepe S: Tolerance to ischemia and hypoxia is reduced in aged human myocardium. J Thorac Cardiovasc Surg 2000; 120:660-7
30. T issier R, Couvreur N, Ghaleh B, Bruneval P, Lidouren F, Morin D, Zini R, Bize A, Chenoune M, Belair MF, Mandet C, Douheret M, Dubois-Rande JL, Parker JC, Cohen MV, Downey JM, Berdeaux A: Rapid cooling preserves the ischaemic myocardium against mitochondrial damage and left ventricular dysfunction. Cardiovasc Res 2009; 83:345-53
31. G ateau-Roesch O, Argaud L, Ovize M: Mitochondrial permeability transition pore and postconditioning. Cardiovasc Res 2006; 70:264-73